GILEAD SCIENCES, INC.

GILD Healthcare & Pharma 4/10 Medium Risk
4/10

GILEAD SCIENCES, INC. has $26.7B in total long-term debt with $30.5B in scheduled maturities. Approximately $2.8B (9% of maturities) is due within the next twelve months, and operating income covers interest expense 7.6x. Overall, GILD carries moderate refinancing risk (score 4/10).

Maturity Schedule

Year 1 $2.8B Year 2 $1.5B Year 3 $4.2B Year 4 $1.8B Year 5 $1.8B Beyond 5 $18.5B
Period Amount Due % of Total
Year 1 (0-12 months) $2.8B 9.0%
Year 2 (12-24 months) $1.5B 4.9%
Year 3 (24-36 months) $4.2B 13.9%
Year 4 (36-48 months) $1.8B 5.7%
Year 5 (48-60 months) $1.8B 5.7%
Beyond 5 Years $18.5B 60.7%
Total Scheduled Maturities $30.5B 100.0%

Key Metrics

Total Long-Term Debt
$26.7B
Near-Term (12mo)
$2.8B
Interest Coverage
7.6x
Debt/Equity
1.38
Cash Coverage
1.94x
Operating Income
$7.6B

Score Components

Component Value Weight
Near-Term Maturity Concentration 9.0% 30%
Interest Coverage Ratio 7.60x 25%
Debt-to-Equity Ratio 1.38 25%
Cash Coverage of Near-Term Debt 1.94x 20%

Related Companies

JOHNSON & JOHNSON
JNJ
1/10
Debt: $32.4B 12mo: $2.0B
PFIZER INC
PFE
5/10
Debt: $4.0B 12mo: N/A
AbbVie Inc.
ABBV
5/10
Debt: $64.5B 12mo: $6.0B
Merck & Co., Inc.
MRK
3/10
Debt: N/A 12mo: $2.6B
ELI LILLY & Co
LLY
3/10
Debt: $19.1B 12mo: $781M
BRISTOL MYERS SQUIBB CO
BMY
4/10
Debt: $49.4B 12mo: $2.0B
AMGEN INC
AMGN
5/10
Debt: $60.1B 12mo: $4.6B
REGENERON PHARMACEUTICALS, INC.
REGN
1/10
Debt: N/A 12mo: N/A

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Most recent filing date: 2026-02-24. Data last fetched: 2026-03-15. Maturity schedules reflect the company's most recently reported debt repayment obligations. Data quality: Complete.